Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Acelyrin, Inc.
Acelyrin, Inc. News
May 13, 2025 - globenewswire.com
ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
May 6, 2025 - globenewswire.com
Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with Alumis
Acelyrin, Inc. Quantitative Score
About Acelyrin, Inc.
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.
Acelyrin, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Acelyrin, Inc. Financials
Table Compare
Compare SLRN metrics with: | |||
|---|---|---|---|
Earnings & Growth | SLRN | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | SLRN | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | SLRN | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | SLRN | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Acelyrin, Inc. Income
Acelyrin, Inc. Balance Sheet
Acelyrin, Inc. Cash Flow
Acelyrin, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Neutral |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Buy |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Buy |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Acelyrin, Inc. Executives
| Name | Role |
|---|---|
| Ms. Mina Kim J.D. | Chief Executive Officer & Director |
| Dr. Shephard Mpofu M.D. | Chief Medical Officer |
| Ms. Patricia A. Turney | Chief Technical Operations Officer |
| Mr. K. Amar Murugan J.D. | Chief Legal Officer |
| Mr. Kenneth A. Lock | Chief Commercial Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Ms. Mina Kim J.D. | Chief Executive Officer & Director | Female | 1974 | 906.64K |
| Dr. Shephard Mpofu M.D. | Chief Medical Officer | 1967 | 679.65K | |
| Ms. Patricia A. Turney | Chief Technical Operations Officer | Female | 1967 | -- |
| Mr. K. Amar Murugan J.D. | Chief Legal Officer | Male | 1976 | -- |
| Mr. Kenneth A. Lock | Chief Commercial Officer | Male | 1974 | -- |
Acelyrin, Inc. Insider Trades
| Date | 21 May |
| Name | AyurMaya Capital Management Company, LP |
| Role | See Remarks |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 9334735 |
| Date | 21 May |
| Name | Kim Mina |
| Role | Chief Executive Officer |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 89526 |
| Date | 21 May |
| Name | Kim Mina |
| Role | Chief Executive Officer |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 770833 |
| Date | 21 May |
| Name | Kim Mina |
| Role | Chief Executive Officer |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 1195856 |
| Date | 21 May |
| Name | Kim Mina |
| Role | Chief Executive Officer |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 190114 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 21 May | AyurMaya Capital Management Company, LP | See Remarks | Disposed | D-Return | 9334735 |
| 21 May | Kim Mina | Chief Executive Officer | Acquired | A-Award | 89526 |
| 21 May | Kim Mina | Chief Executive Officer | Disposed | D-Return | 770833 |
| 21 May | Kim Mina | Chief Executive Officer | Disposed | D-Return | 1195856 |
| 21 May | Kim Mina | Chief Executive Officer | Disposed | D-Return | 190114 |